Market Closed -
Nasdaq
01:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
3.81
USD
|
-0.78%
|
|
+2.42%
|
-18.94%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
184.6
|
62.26
|
141.2
|
176.8
|
636.1
|
530.6
|
-
|
-
|
Enterprise Value (EV)
1 |
184.6
|
62.26
|
141.2
|
176.8
|
636.1
|
530.6
|
530.6
|
530.6
|
P/E ratio
|
-2.3
x
|
-1.37
x
|
-3.88
x
|
-6.2
x
|
-14.2
x
|
-9.26
x
|
-8.86
x
|
-44.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
242
x
|
-
|
-
|
-
|
-
|
152
x
|
9.4
x
|
EV / Revenue
|
-
|
242
x
|
-
|
-
|
-
|
-
|
152
x
|
9.4
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-4.08
x
|
-1.56
x
|
-3.5
x
|
-5.12
x
|
-12.4
x
|
-8.99
x
|
-6.1
x
|
-7.69
x
|
FCF Yield
|
-24.5%
|
-64.1%
|
-28.6%
|
-19.5%
|
-8.07%
|
-11.1%
|
-16.4%
|
-13%
|
Price to Book
|
2.24
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,210
|
54,141
|
1,13,869
|
1,14,044
|
1,35,341
|
1,38,189
|
-
|
-
|
Reference price
2 |
4.480
|
1.150
|
1.240
|
1.550
|
4.700
|
3.810
|
3.810
|
3.810
|
Announcement Date
|
12/03/20
|
10/03/21
|
30/03/22
|
30/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.257
|
-
|
-
|
-
|
-
|
3.48
|
56.44
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-52.17
|
-49.3
|
-41.48
|
-38.84
|
-60.01
|
-82.88
|
-77.87
|
-19.35
|
Operating Margin
|
-
|
-19,182.88%
|
-
|
-
|
-
|
-
|
-2,237.88%
|
-34.28%
|
Earnings before Tax (EBT)
1 |
-78.17
|
-49.62
|
-43.01
|
-38.15
|
-54.7
|
-77.12
|
-72.65
|
-16.09
|
Net income
1 |
-78.17
|
-49.62
|
-43.01
|
-38.15
|
-54.7
|
-76.96
|
-72.65
|
-16.09
|
Net margin
|
-
|
-19,305.45%
|
-
|
-
|
-
|
-
|
-2,087.98%
|
-28.51%
|
EPS
2 |
-1.950
|
-0.8400
|
-0.3200
|
-0.2500
|
-0.3300
|
-0.4114
|
-0.4300
|
-0.0850
|
Free Cash Flow
1 |
-45.27
|
-39.88
|
-40.37
|
-34.55
|
-51.36
|
-59
|
-87
|
-69
|
FCF margin
|
-
|
-15,518.68%
|
-
|
-
|
-
|
-
|
-2,500.24%
|
-122.26%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
10/03/21
|
30/03/22
|
30/03/23
|
07/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-10.64
|
-8.046
|
-9.383
|
-10.54
|
-10.88
|
-12.11
|
-12.22
|
-18.04
|
-17.63
|
-22.48
|
-21.46
|
-19.73
|
-19.2
|
-16.91
|
-17.67
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.31
|
-8.3
|
-9.164
|
-10.39
|
-10.3
|
-10.56
|
-11.44
|
-16.6
|
-16.1
|
-20.35
|
-20.14
|
-18.42
|
-17.89
|
-15.36
|
-16.13
|
Net income
1 |
-11.31
|
-8.3
|
-9.164
|
-10.39
|
-10.3
|
-10.56
|
-11.44
|
-16.6
|
-16.1
|
-20.35
|
-20.14
|
-18.42
|
-17.89
|
-15.36
|
-16.13
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0700
|
-0.0500
|
-0.0600
|
-0.0700
|
-0.0700
|
-0.0700
|
-0.0700
|
-0.1000
|
-0.0900
|
-0.1100
|
-0.1083
|
-0.1000
|
-0.1000
|
-0.0925
|
-0.0950
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/22
|
11/05/22
|
11/08/22
|
10/11/22
|
30/03/23
|
15/05/23
|
10/08/23
|
09/11/23
|
07/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-45.3
|
-39.9
|
-40.4
|
-34.6
|
-51.4
|
-59
|
-87
|
-69
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
2.000
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.15
|
0.05
|
0.06
|
0.01
|
0.3
|
0.52
|
0.52
|
0.52
|
Capex / Sales
|
-
|
18.29%
|
-
|
-
|
-
|
-
|
14.89%
|
0.92%
|
Announcement Date
|
12/03/20
|
10/03/21
|
30/03/22
|
30/03/23
|
07/03/24
|
-
|
-
|
-
|
Last Close Price
3.81
USD Average target price
10.71
USD Spread / Average Target +181.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.94% | 531M | | +16.13% | 122B | | +19.65% | 115B | | +21.22% | 26.64B | | -23.84% | 19.91B | | -17.47% | 16.32B | | -45.95% | 15.52B | | -19.28% | 15.49B | | +63.81% | 14.83B | | +1.94% | 13.67B |
Bio Therapeutic Drugs
|